Valuation: Inhalation Sciences Sweden AB

Market Cap 9.47M 999K 864K 807K 742K 1.4M 95.01M 1.42M 3.71M 47.59M 3.75M 3.67M 159M P/E 2024
-12.8x
P/E 2025 -12.4x
Enterprise Value 6.64M 700K 606K 566K 520K 982K 66.61M 993K 2.6M 33.37M 2.63M 2.57M 111M EV / Sales 2024
5.6x
EV / Sales 2025 55x
Free-Float
94.25%
Yield 2024 *
-
Yield 2025 -
1 week-15.91%
Current month+2.78%
1 month-21.61%
3 months-24.49%
6 months-46.22%
Current year-95.74%
1 week 0.18
Extreme 0.18
0.21
1 month 0.18
Extreme 0.18
0.25
Current year 0.17
Extreme 0.172
0.58
1 year 0.17
Extreme 0.172
0.58
3 years 0.17
Extreme 0.172
4.99
5 years 0.17
Extreme 0.172
11.3
10 years 0.17
Extreme 0.172
15.48
Manager TitleAgeSince
Chief Executive Officer - 16/09/2019
Chief Tech/Sci/R&D Officer - 01/01/2005
Corporate Officer/Principal - 02/06/2025
Director TitleAgeSince
Director/Board Member - 01/01/2005
Director/Board Member - 01/09/2022
Director/Board Member - 01/09/2024
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-15.91%-95.74%-93.62% 992K
+2.32%+0.25%+23.85%+5.32% 209B
+2.51%+0.31%+1.11%-21.63% 137B
+1.88%+3.70%-22.38%+21.30% 130B
-2.75%+3.65%-55.30%-5.88% 71.14B
-0.70%+6.32%+11.09%+11.84% 51.59B
+0.62%+9.24%-15.14%-20.39% 49.99B
+1.37%+0.41%+22.88%+11.73% 39.31B
+0.99%+4.19%+40.06%+37.98% 38.89B
+0.40%+7.21%-23.13%+24.98% 32.19B
Average +0.50%+1.44%-11.27%-2.84% 75.9B
Weighted average by Cap. +1.00%+1.42%-0.24%+3.74%

Financials

2024 2025
Net sales 11.05M 1.17M 1.01M 941K 865K 1.63M 111M 1.65M 4.33M 55.51M 4.38M 4.28M 185M 3.04M 321K 277K 259K 238K 450K 30.5M 455K 1.19M 15.28M 1.2M 1.18M 50.99M
Net income -5.15M -543K -470K -439K -403K -761K -51.63M -769K -2.02M -25.86M -2.04M -1.99M -86.3M -10.16M -1.07M -927K -866K -796K -1.5M -102M -1.52M -3.98M -51.05M -4.02M -3.94M -170M
Net Debt -4M -422K -365K -341K -313K -592K -40.15M -598K -1.57M -20.11M -1.59M -1.55M -67.12M -2.83M -299K -258K -241K -222K -418K -28.4M -423K -1.11M -14.23M -1.12M -1.1M -47.47M
Logo Inhalation Sciences Sweden AB
Inhalation Sciences Sweden AB is a Sweden-based company, which develops and sells labtech equipment for inhalation research. The Company’s primary product is PreciseInhale, which is a laboratory system that lets scientists measure how inhaled particles act in lungs and affect human health. PreciseInhale is a dry powder aerosol research and development system, which generate aerosols and data of a quality. The system helps to eliminate poor candidate drugs before clinical trials. The secondary product is LaminarPace, a tool for drying small amounts of drug substance. The Company’s customers comprise Dow Chemical Group, Kings College London and Karolinska Institutet, among others. The Company’s main shareholder is Nordnet Pensionsforsakring.
Employees
5
Date Price Change Volume
05/08/26 SEK 0.1850 0.00% 9,806
04/08/26 SEK 0.1850 -1.07% 87
03/08/26 SEK 0.1870 +3.89% 19,325
31/07/26 SEK 0.1800 -16.67% 370,147
29/07/26 SEK 0.2160 -1.82% 248,550

Net sales - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ISAB Stock